Amneal Pharmaceuticals announced that it has received abbreviated new drug application, or ANDA, approval from the FDA for Propofol Injectable Emulsion USP, 200 mg/20 mL, 500 mg/50 mL and 1,000 mg/100 mL, single-dose vials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $10 from $8 at Barclays
- Generic Mucinex at risk of containing potent carcinogen, Bloomberg says
- Amneal narrows FY24 adjusted EPS view 57c-63c from 53c-63c, consensus 61c
- Amneal Pharmaceuticals reports Q2 adjusted EPS 16c, consensus 14c
- Closing Bell Movers: Dutch Bros melts over 20% on slower unit growth